nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—hepatitis B	0.554	0.765	CbGaD
Thalidomide—TNF—hepatitis B	0.17	0.235	CbGaD
Thalidomide—TNF—blood—hepatitis B	0.00262	0.117	CbGeAlD
Thalidomide—Pomalidomide—TNF—hepatitis B	0.00185	0.416	CrCbGaD
Thalidomide—Menadione—F2—hepatitis B	0.00167	0.377	CrCbGaD
Thalidomide—NFKB1—blood—hepatitis B	0.00149	0.0665	CbGeAlD
Thalidomide—CYP2C19—blood plasma—hepatitis B	0.00137	0.0612	CbGeAlD
Thalidomide—CRBN—blood—hepatitis B	0.00125	0.0557	CbGeAlD
Thalidomide—Raised liver function tests—Lamivudine—hepatitis B	0.00118	0.00836	CcSEcCtD
Thalidomide—NFKB1—liver—hepatitis B	0.00117	0.052	CbGeAlD
Thalidomide—Hepatocellular injury—Adefovir Dipivoxil—hepatitis B	0.00115	0.00814	CcSEcCtD
Thalidomide—Hyperkalaemia—Adefovir Dipivoxil—hepatitis B	0.00113	0.008	CcSEcCtD
Thalidomide—CYP1A2—blood plasma—hepatitis B	0.00112	0.05	CbGeAlD
Thalidomide—FGFR2—blood—hepatitis B	0.00112	0.0499	CbGeAlD
Thalidomide—CYP3A5—blood plasma—hepatitis B	0.00108	0.0482	CbGeAlD
Thalidomide—Musculoskeletal stiffness—Telbivudine—hepatitis B	0.00108	0.00764	CcSEcCtD
Thalidomide—CYP2C9—blood plasma—hepatitis B	0.00107	0.0475	CbGeAlD
Thalidomide—CYP2E1—blood plasma—hepatitis B	0.00101	0.045	CbGeAlD
Thalidomide—Neck pain—Telbivudine—hepatitis B	0.000979	0.00694	CcSEcCtD
Thalidomide—CRBN—liver—hepatitis B	0.000978	0.0436	CbGeAlD
Thalidomide—PTGS1—blood plasma—hepatitis B	0.000972	0.0433	CbGeAlD
Thalidomide—Suicide attempt—Lamivudine—hepatitis B	0.000961	0.00681	CcSEcCtD
Thalidomide—PTGS2—blood plasma—hepatitis B	0.00093	0.0414	CbGeAlD
Thalidomide—Menadione—CYP2A6—hepatitis B	0.000919	0.207	CrCbGaD
Thalidomide—FGFR2—liver—hepatitis B	0.000876	0.0391	CbGeAlD
Thalidomide—Sepsis—Telbivudine—hepatitis B	0.000839	0.00595	CcSEcCtD
Thalidomide—Blood creatinine increased—Entecavir—hepatitis B	0.000801	0.00567	CcSEcCtD
Thalidomide—Blood creatinine increased—Adefovir Dipivoxil—hepatitis B	0.000781	0.00553	CcSEcCtD
Thalidomide—Hepatomegaly—Lamivudine—hepatitis B	0.00077	0.00546	CcSEcCtD
Thalidomide—Liver function test abnormal—Adefovir Dipivoxil—hepatitis B	0.00077	0.00545	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Adefovir Dipivoxil—hepatitis B	0.000735	0.00521	CcSEcCtD
Thalidomide—Pancreatitis—Entecavir—hepatitis B	0.000724	0.00513	CcSEcCtD
Thalidomide—Pancreatitis—Adefovir Dipivoxil—hepatitis B	0.000707	0.00501	CcSEcCtD
Thalidomide—Amblyopia—Lamivudine—hepatitis B	0.000706	0.005	CcSEcCtD
Thalidomide—Pain in extremity—Telbivudine—hepatitis B	0.000702	0.00497	CcSEcCtD
Thalidomide—Hyperaesthesia—Lamivudine—hepatitis B	0.000694	0.00492	CcSEcCtD
Thalidomide—Migraine—Telbivudine—hepatitis B	0.000691	0.0049	CcSEcCtD
Thalidomide—Neutropenia—Entecavir—hepatitis B	0.000691	0.00489	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Entecavir—hepatitis B	0.000687	0.00486	CcSEcCtD
Thalidomide—Hyperglycaemia—Entecavir—hepatitis B	0.000666	0.00472	CcSEcCtD
Thalidomide—Blood disorder—Lamivudine—hepatitis B	0.000653	0.00462	CcSEcCtD
Thalidomide—Weight decreased—Adefovir Dipivoxil—hepatitis B	0.000652	0.00462	CcSEcCtD
Thalidomide—Acne—Lamivudine—hepatitis B	0.000648	0.00459	CcSEcCtD
Thalidomide—Renal failure—Entecavir—hepatitis B	0.000647	0.00459	CcSEcCtD
Thalidomide—Cramp muscle—Telbivudine—hepatitis B	0.000632	0.00448	CcSEcCtD
Thalidomide—Aspartate aminotransferase increased—Telbivudine—hepatitis B	0.000632	0.00448	CcSEcCtD
Thalidomide—Renal failure—Adefovir Dipivoxil—hepatitis B	0.000632	0.00448	CcSEcCtD
Thalidomide—Haematuria—Entecavir—hepatitis B	0.000628	0.00445	CcSEcCtD
Thalidomide—Vasodilation—Lamivudine—hepatitis B	0.00062	0.0044	CcSEcCtD
Thalidomide—Vasodilation procedure—Lamivudine—hepatitis B	0.00062	0.0044	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Telbivudine—hepatitis B	0.000619	0.00439	CcSEcCtD
Thalidomide—Muscular weakness—Telbivudine—hepatitis B	0.000619	0.00439	CcSEcCtD
Thalidomide—Haematuria—Adefovir Dipivoxil—hepatitis B	0.000613	0.00434	CcSEcCtD
Thalidomide—Abdominal distension—Telbivudine—hepatitis B	0.000611	0.00433	CcSEcCtD
Thalidomide—Influenza—Telbivudine—hepatitis B	0.000607	0.0043	CcSEcCtD
Thalidomide—Viral infection—Lamivudine—hepatitis B	0.000603	0.00428	CcSEcCtD
Thalidomide—Bone disorder—Lamivudine—hepatitis B	0.000603	0.00428	CcSEcCtD
Thalidomide—Sinusitis—Adefovir Dipivoxil—hepatitis B	0.000603	0.00427	CcSEcCtD
Thalidomide—Hepatitis—Entecavir—hepatitis B	0.000591	0.00419	CcSEcCtD
Thalidomide—Drug interaction—Lamivudine—hepatitis B	0.000588	0.00416	CcSEcCtD
Thalidomide—Oedema peripheral—Entecavir—hepatitis B	0.000582	0.00413	CcSEcCtD
Thalidomide—Hepatitis—Adefovir Dipivoxil—hepatitis B	0.000577	0.00409	CcSEcCtD
Thalidomide—Hypercholesterolaemia—Lamivudine—hepatitis B	0.000576	0.00408	CcSEcCtD
Thalidomide—Hearing impaired—Lamivudine—hepatitis B	0.000573	0.00406	CcSEcCtD
Thalidomide—Pharyngitis—Adefovir Dipivoxil—hepatitis B	0.000573	0.00406	CcSEcCtD
Thalidomide—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.00057	0.00404	CcSEcCtD
Thalidomide—Neutropenia—Telbivudine—hepatitis B	0.000567	0.00402	CcSEcCtD
Thalidomide—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.000565	0.00401	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Telbivudine—hepatitis B	0.000564	0.004	CcSEcCtD
Thalidomide—Eructation—Lamivudine—hepatitis B	0.000536	0.00379	CcSEcCtD
Thalidomide—Immune system disorder—Entecavir—hepatitis B	0.000534	0.00378	CcSEcCtD
Thalidomide—Renal failure—Telbivudine—hepatitis B	0.000532	0.00377	CcSEcCtD
Thalidomide—Neuropathy peripheral—Telbivudine—hepatitis B	0.00053	0.00376	CcSEcCtD
Thalidomide—Alopecia—Entecavir—hepatitis B	0.000522	0.0037	CcSEcCtD
Thalidomide—Mental disorder—Entecavir—hepatitis B	0.000518	0.00367	CcSEcCtD
Thalidomide—Malnutrition—Entecavir—hepatitis B	0.000515	0.00365	CcSEcCtD
Thalidomide—Neuropathy—Lamivudine—hepatitis B	0.000512	0.00363	CcSEcCtD
Thalidomide—Aplastic anaemia—Lamivudine—hepatitis B	0.000512	0.00363	CcSEcCtD
Thalidomide—CYP2C19—blood—hepatitis B	0.000503	0.0224	CbGeAlD
Thalidomide—Malnutrition—Adefovir Dipivoxil—hepatitis B	0.000502	0.00356	CcSEcCtD
Thalidomide—Flatulence—Adefovir Dipivoxil—hepatitis B	0.000495	0.00351	CcSEcCtD
Thalidomide—Gynaecomastia—Lamivudine—hepatitis B	0.000488	0.00346	CcSEcCtD
Thalidomide—Back pain—Adefovir Dipivoxil—hepatitis B	0.000486	0.00344	CcSEcCtD
Thalidomide—Hepatitis—Telbivudine—hepatitis B	0.000486	0.00344	CcSEcCtD
Thalidomide—Hypoaesthesia—Telbivudine—hepatitis B	0.000483	0.00342	CcSEcCtD
Thalidomide—Pharyngitis—Telbivudine—hepatitis B	0.000482	0.00342	CcSEcCtD
Thalidomide—Sepsis—Lamivudine—hepatitis B	0.000473	0.00335	CcSEcCtD
Thalidomide—Anaemia—Adefovir Dipivoxil—hepatitis B	0.000464	0.00329	CcSEcCtD
Thalidomide—Lymphadenopathy—Lamivudine—hepatitis B	0.000464	0.00329	CcSEcCtD
Thalidomide—Leukopenia—Entecavir—hepatitis B	0.000461	0.00326	CcSEcCtD
Thalidomide—Gastroenteritis—Lamivudine—hepatitis B	0.000446	0.00316	CcSEcCtD
Thalidomide—Deafness—Lamivudine—hepatitis B	0.000442	0.00313	CcSEcCtD
Thalidomide—Cough—Adefovir Dipivoxil—hepatitis B	0.000438	0.0031	CcSEcCtD
Thalidomide—Mediastinal disorder—Telbivudine—hepatitis B	0.000438	0.0031	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.000435	0.00308	CcSEcCtD
Thalidomide—Injury—Lamivudine—hepatitis B	0.00043	0.00305	CcSEcCtD
Thalidomide—Chest pain—Adefovir Dipivoxil—hepatitis B	0.000428	0.00303	CcSEcCtD
Thalidomide—Myalgia—Adefovir Dipivoxil—hepatitis B	0.000428	0.00303	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.000425	0.00301	CcSEcCtD
Thalidomide—Malnutrition—Telbivudine—hepatitis B	0.000423	0.003	CcSEcCtD
Thalidomide—Infection—Entecavir—hepatitis B	0.000417	0.00296	CcSEcCtD
Thalidomide—Dysgeusia—Telbivudine—hepatitis B	0.000414	0.00293	CcSEcCtD
Thalidomide—Nervous system disorder—Entecavir—hepatitis B	0.000412	0.00292	CcSEcCtD
Thalidomide—CYP1A2—blood—hepatitis B	0.000411	0.0183	CbGeAlD
Thalidomide—Back pain—Telbivudine—hepatitis B	0.000409	0.0029	CcSEcCtD
Thalidomide—Skin disorder—Entecavir—hepatitis B	0.000408	0.00289	CcSEcCtD
Thalidomide—Muscle spasms—Telbivudine—hepatitis B	0.000407	0.00288	CcSEcCtD
Thalidomide—CYP1A1—blood—hepatitis B	0.000406	0.0181	CbGeAlD
Thalidomide—Hypoglycaemia—Lamivudine—hepatitis B	0.000405	0.00287	CcSEcCtD
Thalidomide—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.000402	0.00285	CcSEcCtD
Thalidomide—Thrombocytopenia—Adefovir Dipivoxil—hepatitis B	0.000401	0.00284	CcSEcCtD
Thalidomide—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.000398	0.00282	CcSEcCtD
Thalidomide—CYP3A5—blood—hepatitis B	0.000397	0.0177	CbGeAlD
Thalidomide—CYP2C19—liver—hepatitis B	0.000394	0.0175	CbGeAlD
Thalidomide—Ill-defined disorder—Telbivudine—hepatitis B	0.000392	0.00278	CcSEcCtD
Thalidomide—Anorexia—Adefovir Dipivoxil—hepatitis B	0.000391	0.00277	CcSEcCtD
Thalidomide—CYP2C9—blood—hepatitis B	0.00039	0.0174	CbGeAlD
Thalidomide—Affect lability—Lamivudine—hepatitis B	0.000389	0.00276	CcSEcCtD
Thalidomide—Migraine—Lamivudine—hepatitis B	0.000389	0.00276	CcSEcCtD
Thalidomide—Malaise—Telbivudine—hepatitis B	0.000381	0.0027	CcSEcCtD
Thalidomide—Insomnia—Entecavir—hepatitis B	0.00038	0.00269	CcSEcCtD
Thalidomide—Mood swings—Lamivudine—hepatitis B	0.000375	0.00266	CcSEcCtD
Thalidomide—Somnolence—Entecavir—hepatitis B	0.000373	0.00265	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.000373	0.00265	CcSEcCtD
Thalidomide—CYP2E1—blood—hepatitis B	0.00037	0.0165	CbGeAlD
Thalidomide—Dyspepsia—Entecavir—hepatitis B	0.00037	0.00262	CcSEcCtD
Thalidomide—Cough—Telbivudine—hepatitis B	0.000369	0.00261	CcSEcCtD
Thalidomide—Dehydration—Lamivudine—hepatitis B	0.000368	0.00261	CcSEcCtD
Thalidomide—Liver function test abnormal—Lamivudine—hepatitis B	0.000365	0.00259	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Entecavir—hepatitis B	0.000363	0.00257	CcSEcCtD
Thalidomide—Fatigue—Entecavir—hepatitis B	0.000362	0.00257	CcSEcCtD
Thalidomide—Dyspepsia—Adefovir Dipivoxil—hepatitis B	0.000361	0.00256	CcSEcCtD
Thalidomide—Myalgia—Telbivudine—hepatitis B	0.00036	0.00255	CcSEcCtD
Thalidomide—Chest pain—Telbivudine—hepatitis B	0.00036	0.00255	CcSEcCtD
Thalidomide—Arthralgia—Telbivudine—hepatitis B	0.00036	0.00255	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.000357	0.00253	CcSEcCtD
Thalidomide—Cramp muscle—Lamivudine—hepatitis B	0.000356	0.00252	CcSEcCtD
Thalidomide—Aspartate aminotransferase increased—Lamivudine—hepatitis B	0.000356	0.00252	CcSEcCtD
Thalidomide—Decreased appetite—Adefovir Dipivoxil—hepatitis B	0.000356	0.00252	CcSEcCtD
Thalidomide—PTGS1—blood—hepatitis B	0.000356	0.0159	CbGeAlD
Thalidomide—Discomfort—Telbivudine—hepatitis B	0.000356	0.00252	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.000354	0.00251	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Lamivudine—hepatitis B	0.000349	0.00247	CcSEcCtD
Thalidomide—Muscular weakness—Lamivudine—hepatitis B	0.000349	0.00247	CcSEcCtD
Thalidomide—Abdominal distension—Lamivudine—hepatitis B	0.000344	0.00244	CcSEcCtD
Thalidomide—Gastrointestinal pain—Entecavir—hepatitis B	0.000343	0.00243	CcSEcCtD
Thalidomide—Influenza—Lamivudine—hepatitis B	0.000342	0.00242	CcSEcCtD
Thalidomide—Dysphagia—Lamivudine—hepatitis B	0.000342	0.00242	CcSEcCtD
Thalidomide—PTGS2—blood—hepatitis B	0.000341	0.0152	CbGeAlD
Thalidomide—Nervous system disorder—Telbivudine—hepatitis B	0.000338	0.0024	CcSEcCtD
Thalidomide—Thrombocytopenia—Telbivudine—hepatitis B	0.000338	0.00239	CcSEcCtD
Thalidomide—Pancreatitis—Lamivudine—hepatitis B	0.000335	0.00238	CcSEcCtD
Thalidomide—Skin disorder—Telbivudine—hepatitis B	0.000335	0.00237	CcSEcCtD
Thalidomide—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.000335	0.00237	CcSEcCtD
Thalidomide—Abdominal pain—Entecavir—hepatitis B	0.000332	0.00235	CcSEcCtD
Thalidomide—Body temperature increased—Entecavir—hepatitis B	0.000332	0.00235	CcSEcCtD
Thalidomide—Bronchitis—Lamivudine—hepatitis B	0.000329	0.00233	CcSEcCtD
Thalidomide—Pancytopenia—Lamivudine—hepatitis B	0.000325	0.0023	CcSEcCtD
Thalidomide—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.000324	0.0023	CcSEcCtD
Thalidomide—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.000324	0.0023	CcSEcCtD
Thalidomide—CYP1A2—liver—hepatitis B	0.000321	0.0143	CbGeAlD
Thalidomide—Neutropenia—Lamivudine—hepatitis B	0.00032	0.00227	CcSEcCtD
Thalidomide—CYP1A1—liver—hepatitis B	0.000317	0.0141	CbGeAlD
Thalidomide—Pollakiuria—Lamivudine—hepatitis B	0.000316	0.00224	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.000314	0.00223	CcSEcCtD
Thalidomide—Insomnia—Telbivudine—hepatitis B	0.000312	0.00221	CcSEcCtD
Thalidomide—CYP3A5—liver—hepatitis B	0.00031	0.0138	CbGeAlD
Thalidomide—Paraesthesia—Telbivudine—hepatitis B	0.00031	0.0022	CcSEcCtD
Thalidomide—Hyperglycaemia—Lamivudine—hepatitis B	0.000308	0.00219	CcSEcCtD
Thalidomide—CYP2C9—liver—hepatitis B	0.000305	0.0136	CbGeAlD
Thalidomide—Depression—Lamivudine—hepatitis B	0.000304	0.00215	CcSEcCtD
Thalidomide—Dyspepsia—Telbivudine—hepatitis B	0.000304	0.00215	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Lamivudine—hepatitis B	0.000302	0.00214	CcSEcCtD
Thalidomide—Asthenia—Entecavir—hepatitis B	0.000301	0.00214	CcSEcCtD
Thalidomide—Renal failure—Lamivudine—hepatitis B	0.0003	0.00212	CcSEcCtD
Thalidomide—Neuropathy peripheral—Lamivudine—hepatitis B	0.000299	0.00212	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Telbivudine—hepatitis B	0.000298	0.00211	CcSEcCtD
Thalidomide—Fatigue—Telbivudine—hepatitis B	0.000298	0.00211	CcSEcCtD
Thalidomide—Stomatitis—Lamivudine—hepatitis B	0.000297	0.00211	CcSEcCtD
Thalidomide—Pain—Telbivudine—hepatitis B	0.000295	0.00209	CcSEcCtD
Thalidomide—Asthenia—Adefovir Dipivoxil—hepatitis B	0.000294	0.00208	CcSEcCtD
Thalidomide—Sweating—Lamivudine—hepatitis B	0.000292	0.00207	CcSEcCtD
Thalidomide—Pruritus—Adefovir Dipivoxil—hepatitis B	0.00029	0.00205	CcSEcCtD
Thalidomide—CYP2E1—liver—hepatitis B	0.000289	0.0129	CbGeAlD
Thalidomide—Epistaxis—Lamivudine—hepatitis B	0.000288	0.00204	CcSEcCtD
Thalidomide—Diarrhoea—Entecavir—hepatitis B	0.000287	0.00204	CcSEcCtD
Thalidomide—Sinusitis—Lamivudine—hepatitis B	0.000286	0.00203	CcSEcCtD
Thalidomide—Agranulocytosis—Lamivudine—hepatitis B	0.000285	0.00202	CcSEcCtD
Thalidomide—Feeling abnormal—Telbivudine—hepatitis B	0.000284	0.00201	CcSEcCtD
Thalidomide—Gastrointestinal pain—Telbivudine—hepatitis B	0.000282	0.002	CcSEcCtD
Thalidomide—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.00028	0.00199	CcSEcCtD
Thalidomide—Dizziness—Entecavir—hepatitis B	0.000278	0.00197	CcSEcCtD
Thalidomide—Rhinitis—Lamivudine—hepatitis B	0.000274	0.00194	CcSEcCtD
Thalidomide—Hepatitis—Lamivudine—hepatitis B	0.000274	0.00194	CcSEcCtD
Thalidomide—Abdominal pain—Telbivudine—hepatitis B	0.000273	0.00193	CcSEcCtD
Thalidomide—Body temperature increased—Telbivudine—hepatitis B	0.000273	0.00193	CcSEcCtD
Thalidomide—Hypoaesthesia—Lamivudine—hepatitis B	0.000272	0.00193	CcSEcCtD
Thalidomide—Pharyngitis—Lamivudine—hepatitis B	0.000272	0.00192	CcSEcCtD
Thalidomide—Vomiting—Entecavir—hepatitis B	0.000267	0.00189	CcSEcCtD
Thalidomide—PTGS2—liver—hepatitis B	0.000266	0.0119	CbGeAlD
Thalidomide—Rash—Entecavir—hepatitis B	0.000265	0.00188	CcSEcCtD
Thalidomide—Dermatitis—Entecavir—hepatitis B	0.000265	0.00187	CcSEcCtD
Thalidomide—Headache—Entecavir—hepatitis B	0.000263	0.00186	CcSEcCtD
Thalidomide—Vomiting—Adefovir Dipivoxil—hepatitis B	0.000261	0.00185	CcSEcCtD
Thalidomide—Erythema multiforme—Lamivudine—hepatitis B	0.000259	0.00183	CcSEcCtD
Thalidomide—Rash—Adefovir Dipivoxil—hepatitis B	0.000258	0.00183	CcSEcCtD
Thalidomide—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.000258	0.00183	CcSEcCtD
Thalidomide—Headache—Adefovir Dipivoxil—hepatitis B	0.000257	0.00182	CcSEcCtD
Thalidomide—Nausea—Entecavir—hepatitis B	0.00025	0.00177	CcSEcCtD
Thalidomide—Asthenia—Telbivudine—hepatitis B	0.000248	0.00175	CcSEcCtD
Thalidomide—Immune system disorder—Lamivudine—hepatitis B	0.000247	0.00175	CcSEcCtD
Thalidomide—Mediastinal disorder—Lamivudine—hepatitis B	0.000247	0.00175	CcSEcCtD
Thalidomide—Chills—Lamivudine—hepatitis B	0.000246	0.00174	CcSEcCtD
Thalidomide—Pruritus—Telbivudine—hepatitis B	0.000244	0.00173	CcSEcCtD
Thalidomide—Nausea—Adefovir Dipivoxil—hepatitis B	0.000243	0.00172	CcSEcCtD
Thalidomide—Alopecia—Lamivudine—hepatitis B	0.000242	0.00171	CcSEcCtD
Thalidomide—Malnutrition—Lamivudine—hepatitis B	0.000238	0.00169	CcSEcCtD
Thalidomide—Diarrhoea—Telbivudine—hepatitis B	0.000236	0.00167	CcSEcCtD
Thalidomide—Flatulence—Lamivudine—hepatitis B	0.000235	0.00166	CcSEcCtD
Thalidomide—Tension—Lamivudine—hepatitis B	0.000234	0.00166	CcSEcCtD
Thalidomide—Dysgeusia—Lamivudine—hepatitis B	0.000233	0.00165	CcSEcCtD
Thalidomide—Nervousness—Lamivudine—hepatitis B	0.000231	0.00164	CcSEcCtD
Thalidomide—Back pain—Lamivudine—hepatitis B	0.00023	0.00163	CcSEcCtD
Thalidomide—Muscle spasms—Lamivudine—hepatitis B	0.000229	0.00162	CcSEcCtD
Thalidomide—Dizziness—Telbivudine—hepatitis B	0.000228	0.00162	CcSEcCtD
Thalidomide—Tremor—Lamivudine—hepatitis B	0.000223	0.00158	CcSEcCtD
Thalidomide—Ill-defined disorder—Lamivudine—hepatitis B	0.000221	0.00157	CcSEcCtD
Thalidomide—Anaemia—Lamivudine—hepatitis B	0.00022	0.00156	CcSEcCtD
Thalidomide—Vomiting—Telbivudine—hepatitis B	0.000219	0.00155	CcSEcCtD
Thalidomide—Angioedema—Lamivudine—hepatitis B	0.000218	0.00154	CcSEcCtD
Thalidomide—Rash—Telbivudine—hepatitis B	0.000218	0.00154	CcSEcCtD
Thalidomide—Dermatitis—Telbivudine—hepatitis B	0.000217	0.00154	CcSEcCtD
Thalidomide—Headache—Telbivudine—hepatitis B	0.000216	0.00153	CcSEcCtD
Thalidomide—Malaise—Lamivudine—hepatitis B	0.000215	0.00152	CcSEcCtD
Thalidomide—Vertigo—Lamivudine—hepatitis B	0.000214	0.00152	CcSEcCtD
Thalidomide—Syncope—Lamivudine—hepatitis B	0.000214	0.00151	CcSEcCtD
Thalidomide—Leukopenia—Lamivudine—hepatitis B	0.000213	0.00151	CcSEcCtD
Thalidomide—Loss of consciousness—Lamivudine—hepatitis B	0.000209	0.00148	CcSEcCtD
Thalidomide—Cough—Lamivudine—hepatitis B	0.000208	0.00147	CcSEcCtD
Thalidomide—Convulsion—Lamivudine—hepatitis B	0.000206	0.00146	CcSEcCtD
Thalidomide—Nausea—Telbivudine—hepatitis B	0.000205	0.00145	CcSEcCtD
Thalidomide—Chest pain—Lamivudine—hepatitis B	0.000203	0.00144	CcSEcCtD
Thalidomide—Myalgia—Lamivudine—hepatitis B	0.000203	0.00144	CcSEcCtD
Thalidomide—Arthralgia—Lamivudine—hepatitis B	0.000203	0.00144	CcSEcCtD
Thalidomide—Anxiety—Lamivudine—hepatitis B	0.000202	0.00143	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.000201	0.00143	CcSEcCtD
Thalidomide—Discomfort—Lamivudine—hepatitis B	0.0002	0.00142	CcSEcCtD
Thalidomide—Dry mouth—Lamivudine—hepatitis B	0.000198	0.00141	CcSEcCtD
Thalidomide—Confusional state—Lamivudine—hepatitis B	0.000196	0.00139	CcSEcCtD
Thalidomide—Oedema—Lamivudine—hepatitis B	0.000194	0.00138	CcSEcCtD
Thalidomide—Infection—Lamivudine—hepatitis B	0.000193	0.00137	CcSEcCtD
Thalidomide—Shock—Lamivudine—hepatitis B	0.000191	0.00136	CcSEcCtD
Thalidomide—Nervous system disorder—Lamivudine—hepatitis B	0.000191	0.00135	CcSEcCtD
Thalidomide—Thrombocytopenia—Lamivudine—hepatitis B	0.00019	0.00135	CcSEcCtD
Thalidomide—Skin disorder—Lamivudine—hepatitis B	0.000189	0.00134	CcSEcCtD
Thalidomide—Hyperhidrosis—Lamivudine—hepatitis B	0.000188	0.00133	CcSEcCtD
Thalidomide—Anorexia—Lamivudine—hepatitis B	0.000185	0.00131	CcSEcCtD
Thalidomide—Hypotension—Lamivudine—hepatitis B	0.000182	0.00129	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.000177	0.00126	CcSEcCtD
Thalidomide—Insomnia—Lamivudine—hepatitis B	0.000176	0.00125	CcSEcCtD
Thalidomide—Paraesthesia—Lamivudine—hepatitis B	0.000175	0.00124	CcSEcCtD
Thalidomide—Dyspnoea—Lamivudine—hepatitis B	0.000173	0.00123	CcSEcCtD
Thalidomide—Somnolence—Lamivudine—hepatitis B	0.000173	0.00122	CcSEcCtD
Thalidomide—Dyspepsia—Lamivudine—hepatitis B	0.000171	0.00121	CcSEcCtD
Thalidomide—Decreased appetite—Lamivudine—hepatitis B	0.000169	0.0012	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Lamivudine—hepatitis B	0.000168	0.00119	CcSEcCtD
Thalidomide—Fatigue—Lamivudine—hepatitis B	0.000168	0.00119	CcSEcCtD
Thalidomide—Pain—Lamivudine—hepatitis B	0.000166	0.00118	CcSEcCtD
Thalidomide—Constipation—Lamivudine—hepatitis B	0.000166	0.00118	CcSEcCtD
Thalidomide—Feeling abnormal—Lamivudine—hepatitis B	0.00016	0.00114	CcSEcCtD
Thalidomide—Gastrointestinal pain—Lamivudine—hepatitis B	0.000159	0.00113	CcSEcCtD
Thalidomide—Urticaria—Lamivudine—hepatitis B	0.000154	0.00109	CcSEcCtD
Thalidomide—Abdominal pain—Lamivudine—hepatitis B	0.000154	0.00109	CcSEcCtD
Thalidomide—Body temperature increased—Lamivudine—hepatitis B	0.000154	0.00109	CcSEcCtD
Thalidomide—Hypersensitivity—Lamivudine—hepatitis B	0.000143	0.00102	CcSEcCtD
Thalidomide—Asthenia—Lamivudine—hepatitis B	0.00014	0.000989	CcSEcCtD
Thalidomide—Pruritus—Lamivudine—hepatitis B	0.000138	0.000975	CcSEcCtD
Thalidomide—Diarrhoea—Lamivudine—hepatitis B	0.000133	0.000943	CcSEcCtD
Thalidomide—Dizziness—Lamivudine—hepatitis B	0.000129	0.000911	CcSEcCtD
Thalidomide—Vomiting—Lamivudine—hepatitis B	0.000124	0.000876	CcSEcCtD
Thalidomide—Rash—Lamivudine—hepatitis B	0.000123	0.000869	CcSEcCtD
Thalidomide—Dermatitis—Lamivudine—hepatitis B	0.000123	0.000868	CcSEcCtD
Thalidomide—Headache—Lamivudine—hepatitis B	0.000122	0.000863	CcSEcCtD
Thalidomide—Nausea—Lamivudine—hepatitis B	0.000116	0.000818	CcSEcCtD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—hepatitis B	3.57e-05	0.00033	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HSPA5—hepatitis B	3.55e-05	0.000327	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TGFB1—hepatitis B	3.53e-05	0.000326	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IL6—hepatitis B	3.53e-05	0.000326	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—hepatitis B	3.52e-05	0.000325	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—hepatitis B	3.49e-05	0.000322	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—IL6—hepatitis B	3.48e-05	0.000321	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—CDKN1A—hepatitis B	3.48e-05	0.000321	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—PTEN—hepatitis B	3.47e-05	0.00032	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—NFKB1—hepatitis B	3.45e-05	0.000319	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	3.45e-05	0.000318	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—IL6—hepatitis B	3.43e-05	0.000317	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—hepatitis B	3.42e-05	0.000316	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—TLR4—hepatitis B	3.42e-05	0.000316	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—IL6—hepatitis B	3.41e-05	0.000315	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-A—hepatitis B	3.4e-05	0.000314	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—IL6—hepatitis B	3.4e-05	0.000314	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—IL6—hepatitis B	3.38e-05	0.000312	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HSPA5—hepatitis B	3.36e-05	0.000311	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—IL6—hepatitis B	3.35e-05	0.000309	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DPB1—hepatitis B	3.35e-05	0.000309	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-DRB1—hepatitis B	3.28e-05	0.000303	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—IL6—hepatitis B	3.27e-05	0.000302	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—hepatitis B	3.25e-05	0.0003	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—hepatitis B	3.25e-05	0.0003	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—TLR4—hepatitis B	3.24e-05	0.000299	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TLR2—hepatitis B	3.22e-05	0.000297	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—IL6—hepatitis B	3.22e-05	0.000297	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNB1—hepatitis B	3.2e-05	0.000295	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	3.19e-05	0.000294	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—IL6—hepatitis B	3.18e-05	0.000294	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—IL6—hepatitis B	3.18e-05	0.000294	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—IL6—hepatitis B	3.18e-05	0.000294	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DPB1—hepatitis B	3.18e-05	0.000293	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SAG—hepatitis B	3.17e-05	0.000293	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOBEC3G—hepatitis B	3.17e-05	0.000293	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—IL6—hepatitis B	3.15e-05	0.000291	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—IL6—hepatitis B	3.12e-05	0.000288	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNA1—hepatitis B	3.12e-05	0.000288	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-DRB1—hepatitis B	3.11e-05	0.000287	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—IL6—hepatitis B	3.11e-05	0.000287	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—hepatitis B	3.1e-05	0.000286	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—hepatitis B	3.1e-05	0.000286	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	3.08e-05	0.000285	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TLR2—hepatitis B	3.06e-05	0.000282	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—hepatitis B	3.05e-05	0.000282	CbGpPWpGaD
Thalidomide—FGFR2—Disease—GOT2—hepatitis B	3.04e-05	0.00028	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNB1—hepatitis B	3.03e-05	0.00028	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKR1B1—hepatitis B	3.03e-05	0.00028	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNA1—hepatitis B	2.96e-05	0.000273	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—hepatitis B	2.91e-05	0.000269	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD14—hepatitis B	2.9e-05	0.000268	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNA2—hepatitis B	2.9e-05	0.000268	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GGT2—hepatitis B	2.9e-05	0.000268	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TGFB1—hepatitis B	2.9e-05	0.000268	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL6—hepatitis B	2.83e-05	0.000261	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—IL6—hepatitis B	2.82e-05	0.00026	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL6—hepatitis B	2.76e-05	0.000255	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD14—hepatitis B	2.76e-05	0.000254	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNA2—hepatitis B	2.76e-05	0.000254	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—hepatitis B	2.71e-05	0.00025	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—hepatitis B	2.66e-05	0.000246	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	2.62e-05	0.000242	CbGpPWpGaD
Thalidomide—FGFR2—Disease—GOT1—hepatitis B	2.62e-05	0.000242	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL18—hepatitis B	2.48e-05	0.000229	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD40LG—hepatitis B	2.47e-05	0.000228	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	2.45e-05	0.000226	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD8A—hepatitis B	2.44e-05	0.000225	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—hepatitis B	2.44e-05	0.000225	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL6—hepatitis B	2.43e-05	0.000225	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CTNNB1—hepatitis B	2.42e-05	0.000224	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD4—hepatitis B	2.41e-05	0.000222	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKR1B1—hepatitis B	2.4e-05	0.000222	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—hepatitis B	2.39e-05	0.00022	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—hepatitis B	2.38e-05	0.00022	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—hepatitis B	2.38e-05	0.00022	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—hepatitis B	2.37e-05	0.000219	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL18—hepatitis B	2.35e-05	0.000217	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD40LG—hepatitis B	2.34e-05	0.000216	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—hepatitis B	2.32e-05	0.000214	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD8A—hepatitis B	2.32e-05	0.000214	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD4—hepatitis B	2.31e-05	0.000213	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GGT2—hepatitis B	2.3e-05	0.000213	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD4—hepatitis B	2.28e-05	0.000211	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—hepatitis B	2.28e-05	0.000211	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKR1B1—hepatitis B	2.26e-05	0.000209	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKR1B1—hepatitis B	2.26e-05	0.000208	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD4—hepatitis B	2.19e-05	0.000203	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—hepatitis B	2.18e-05	0.000202	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-A—hepatitis B	2.18e-05	0.000201	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	2.17e-05	0.000201	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GGT2—hepatitis B	2.17e-05	0.0002	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—hepatitis B	2.17e-05	0.0002	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GGT2—hepatitis B	2.17e-05	0.0002	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CTNNB1—hepatitis B	2.14e-05	0.000197	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKR1B1—hepatitis B	2.13e-05	0.000197	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CDKN1A—hepatitis B	2.09e-05	0.000193	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PTEN—hepatitis B	2.08e-05	0.000192	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-A—hepatitis B	2.07e-05	0.000191	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GGT2—hepatitis B	2.05e-05	0.000189	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CTNNB1—hepatitis B	2.03e-05	0.000187	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CDKN1A—hepatitis B	2.01e-05	0.000185	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PTEN—hepatitis B	2e-05	0.000185	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TLR4—hepatitis B	1.99e-05	0.000184	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DRB1—hepatitis B	1.99e-05	0.000184	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CDKN1A—hepatitis B	1.98e-05	0.000183	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PTEN—hepatitis B	1.98e-05	0.000183	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	1.97e-05	0.000182	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NFKB1—hepatitis B	1.97e-05	0.000182	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TGFB1—hepatitis B	1.96e-05	0.000181	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CCR5—hepatitis B	1.96e-05	0.000181	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HLA-A—hepatitis B	1.91e-05	0.000176	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CDKN1A—hepatitis B	1.9e-05	0.000176	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PTEN—hepatitis B	1.9e-05	0.000175	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NFKB1—hepatitis B	1.89e-05	0.000175	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TLR4—hepatitis B	1.89e-05	0.000174	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DRB1—hepatitis B	1.89e-05	0.000174	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL10—hepatitis B	1.86e-05	0.000172	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CTNNB1—hepatitis B	1.85e-05	0.00017	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—hepatitis B	1.84e-05	0.00017	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—hepatitis B	1.83e-05	0.000169	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NFKB1—hepatitis B	1.79e-05	0.000165	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	1.78e-05	0.000164	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL10—hepatitis B	1.77e-05	0.000163	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP2A6—hepatitis B	1.76e-05	0.000162	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKR1B1—hepatitis B	1.75e-05	0.000161	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GGT2—hepatitis B	1.67e-05	0.000155	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS2—hepatitis B	1.66e-05	0.000153	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ALB—hepatitis B	1.64e-05	0.000151	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	1.62e-05	0.00015	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	1.62e-05	0.00015	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKR1B1—hepatitis B	1.59e-05	0.000147	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GOT2—hepatitis B	1.59e-05	0.000147	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GGT2—hepatitis B	1.53e-05	0.000141	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GOT2—hepatitis B	1.51e-05	0.000139	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TGFB1—hepatitis B	1.49e-05	0.000138	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—hepatitis B	1.47e-05	0.000136	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNG—hepatitis B	1.45e-05	0.000134	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCR5—hepatitis B	1.44e-05	0.000133	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD4—hepatitis B	1.4e-05	0.000129	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP2A6—hepatitis B	1.4e-05	0.000129	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	1.39e-05	0.000128	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNG—hepatitis B	1.38e-05	0.000127	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GGT1—hepatitis B	1.37e-05	0.000127	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GOT1—hepatitis B	1.37e-05	0.000127	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR5—hepatitis B	1.37e-05	0.000126	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKR1B1—hepatitis B	1.36e-05	0.000126	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD4—hepatitis B	1.33e-05	0.000123	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP2A6—hepatitis B	1.31e-05	0.000121	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP2A6—hepatitis B	1.31e-05	0.000121	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GGT2—hepatitis B	1.3e-05	0.00012	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—hepatitis B	1.3e-05	0.00012	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—hepatitis B	1.3e-05	0.00012	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GOT1—hepatitis B	1.3e-05	0.00012	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—hepatitis B	1.29e-05	0.000119	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GOT2—hepatitis B	1.26e-05	0.000117	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	1.25e-05	0.000116	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CTNNB1—hepatitis B	1.25e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2A6—hepatitis B	1.24e-05	0.000114	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—F2—hepatitis B	1.24e-05	0.000114	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—hepatitis B	1.24e-05	0.000114	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD4—hepatitis B	1.23e-05	0.000113	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—hepatitis B	1.22e-05	0.000113	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDKN1A—hepatitis B	1.22e-05	0.000112	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PTEN—hepatitis B	1.21e-05	0.000112	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GOT2—hepatitis B	1.19e-05	0.00011	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GOT2—hepatitis B	1.19e-05	0.00011	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CTNNB1—hepatitis B	1.18e-05	0.000109	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—F2—hepatitis B	1.18e-05	0.000109	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—hepatitis B	1.16e-05	0.000107	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDKN1A—hepatitis B	1.15e-05	0.000107	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PTEN—hepatitis B	1.15e-05	0.000106	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NFKB1—hepatitis B	1.15e-05	0.000106	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—hepatitis B	1.12e-05	0.000104	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GOT2—hepatitis B	1.12e-05	0.000103	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CTNNB1—hepatitis B	1.09e-05	0.000101	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GOT1—hepatitis B	1.09e-05	0.000101	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GGT1—hepatitis B	1.09e-05	0.000101	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDKN1A—hepatitis B	1.07e-05	9.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTEN—hepatitis B	1.06e-05	9.82e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GGT1—hepatitis B	1.03e-05	9.47e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GOT1—hepatitis B	1.03e-05	9.47e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GGT1—hepatitis B	1.02e-05	9.45e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GOT1—hepatitis B	1.02e-05	9.45e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2A6—hepatitis B	1.01e-05	9.36e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	9.93e-06	9.17e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CCR5—hepatitis B	9.72e-06	8.97e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GGT1—hepatitis B	9.67e-06	8.93e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GOT1—hepatitis B	9.67e-06	8.93e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HLA-A—hepatitis B	9.47e-06	8.74e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hepatitis B	9.46e-06	8.73e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2A6—hepatitis B	9.25e-06	8.54e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GOT2—hepatitis B	9.17e-06	8.47e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—hepatitis B	8.82e-06	8.14e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	8.82e-06	8.14e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hepatitis B	8.62e-06	7.96e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GOT2—hepatitis B	8.36e-06	7.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—hepatitis B	8.34e-06	7.7e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—hepatitis B	8.24e-06	7.6e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CTNNB1—hepatitis B	8.05e-06	7.44e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GOT1—hepatitis B	7.92e-06	7.31e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GGT1—hepatitis B	7.92e-06	7.31e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—hepatitis B	7.92e-06	7.31e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2A6—hepatitis B	7.9e-06	7.29e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1A—hepatitis B	7.87e-06	7.26e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—hepatitis B	7.85e-06	7.25e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CTNNB1—hepatitis B	7.64e-06	7.05e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—hepatitis B	7.58e-06	7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1A—hepatitis B	7.47e-06	6.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—hepatitis B	7.45e-06	6.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NFKB1—hepatitis B	7.41e-06	6.84e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hepatitis B	7.37e-06	6.8e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—hepatitis B	7.3e-06	6.74e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GGT1—hepatitis B	7.22e-06	6.66e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GOT1—hepatitis B	7.22e-06	6.66e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	7.21e-06	6.66e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—hepatitis B	7.2e-06	6.64e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT2—hepatitis B	7.15e-06	6.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—hepatitis B	6.64e-06	6.13e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	6.58e-06	6.07e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—hepatitis B	6.51e-06	6.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—hepatitis B	6.17e-06	5.7e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT1—hepatitis B	6.17e-06	5.69e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GGT1—hepatitis B	6.17e-06	5.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—hepatitis B	6.1e-06	5.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—hepatitis B	5.8e-06	5.35e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	5.62e-06	5.19e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—hepatitis B	5.57e-06	5.14e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—hepatitis B	5.46e-06	5.04e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—hepatitis B	5.45e-06	5.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CTNNB1—hepatitis B	5.42e-06	5e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—hepatitis B	5.36e-06	4.95e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1A—hepatitis B	5.29e-06	4.89e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—hepatitis B	5.28e-06	4.88e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—hepatitis B	5.15e-06	4.75e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—hepatitis B	5.08e-06	4.69e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—hepatitis B	4.9e-06	4.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—hepatitis B	4.65e-06	4.3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—hepatitis B	4.42e-06	4.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—hepatitis B	4.38e-06	4.04e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—hepatitis B	4.21e-06	3.89e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—hepatitis B	4.16e-06	3.84e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—hepatitis B	4.16e-06	3.84e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—hepatitis B	3.93e-06	3.62e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—hepatitis B	3.84e-06	3.54e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—hepatitis B	3.3e-06	3.05e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—hepatitis B	3.28e-06	3.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—hepatitis B	3.21e-06	2.97e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—hepatitis B	2.93e-06	2.7e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—hepatitis B	2.5e-06	2.31e-05	CbGpPWpGaD
